- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03963310
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis (OCTON2)
February 11, 2023 updated by: Fondation Ophtalmologique Adolphe de Rothschild
Evaluation and Follow-up of Optic Neuritis Not Related to Multiple Sclerosis
The visual prognosis of optic neuritis not related to multiple sclerosis is unknown, both in terms of functional recovery and evolution.
This prospective cohort study aim to assess the ophthalmological evolution of patients presenting an episode of optic neuritis (NO) not related to a multiple sclerosis or to a clinically isolated syndrome.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75019
- Recruiting
- Fondation A. de Rothschild
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients seen at the Adolphe de Rothschild Foundation for the first onset of an optic neuritis not related to multiple sclerosis and clinically isolated syndrome
Description
Inclusion Criteria:
- First onset of an optic neuritis lasting for less than 1 month
- With a brain MRI that does not meet the MS criteria
Exclusion Criteria:
- Contra-indication to MRI
- Pregnant or lactating woman
- History of known ipsilateral optic neuritis
- Ophthalmologic comorbidity in the ipsilateral eye that may interfere with the interpretation of the examinations
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual acuity (ETDRS scale)
Time Frame: 1 year
|
Evolution over 1 year of the ophthalmological parameters of patients treated for an episode of optic neuritis not related to multiple sclerosis or a clinically isolated syndrome
|
1 year
|
Thickness of the layers of the retina with Optical Coherent Tomography(OCT),
Time Frame: 1 year
|
1 year
|
|
Standard Humphrey Visual Field Test
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 14, 2020
Primary Completion (ANTICIPATED)
September 14, 2024
Study Completion (ANTICIPATED)
September 14, 2024
Study Registration Dates
First Submitted
May 20, 2019
First Submitted That Met QC Criteria
May 22, 2019
First Posted (ACTUAL)
May 24, 2019
Study Record Updates
Last Update Posted (ESTIMATE)
February 14, 2023
Last Update Submitted That Met QC Criteria
February 11, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Eye Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Multiple Sclerosis
- Neuritis
- Optic Neuritis
Other Study ID Numbers
- RDS_2019_8
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Optic Neuritis
-
Medical University of ViennaUnknownOptic; Neuritis, With DemyelinationAustria
-
BiogenCompletedAcute Optic NeuritisSweden, Australia, Italy, Spain, United Kingdom, Germany, Belgium, Denmark, Hungary, Czech Republic, Canada
-
Novartis PharmaceuticalsTerminatedAcute Demylelinating Optic NeuritisUnited States, Spain
-
BiogenCompletedAcute Optic NeuritisSweden, Spain, United Kingdom, Germany, Canada, Denmark, Hungary, Belgium, Czechia, Australia, Italy
-
Accure TherapeuticsSimbec ResearchCompletedOptic Neuritis | Optic; Neuritis, With DemyelinationUnited Kingdom
-
OculisNeurotrialsRecruitingOptic Neuritis | Optic; Neuritis, With DemyelinationFrance
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of ZurichUniversity Hospital, Zürich; Swiss MS Society; Data Management, Clinical Trials...TerminatedAcute Autoimmune Inflammatory Optic NeuritisSwitzerland
-
Chinese PLA General HospitalRecruiting
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed